Abstract 115P
Background
Cholangiocarcinoma is the most common primary cancer of liver in North-Eastern region of Thailand. Human epidermal growth factor receptor-2 (HER-2) overexpression is a poor prognostic factor of many types of cancer but there is limited data in cholangiocarcinoma. This study aimed to investigate prevalence of HER-2 overexpression in cholangiocarcinoma and analyzed its association with overall survival and clinicopathological features.
Methods
This study was retrospective cohort analytical single-centered study which included adult patients with cholangiocarcinoma in Srinagarind hospital, Khon Kaen, Thailand. HER-2 expression was classified as positive and negative group. Prevalence of HER-2 overexpression was presented with percentage and 95% confidence interval (95% CI).
Results
A total of 93 cases, of which 71% were male, were included. Mean age was 63 and 62 years in HER-2 positive and negative groups, respectively. The proportion of intrahepatic was more than extrahepatic cholangiocarcinoma (72% vs 28%). HER-2 positive was revealed 10.8% (95% CI 5.3% to 18.9%), composed of 9 cases (13.4%) of patients with intrahepatic cholangiocarcinoma and 1 case (3.8%) of patients with extrahepatic cholangiocarcinoma. The prevalence of HER-2 staining intensity 2+ and 1+ were 14.0% (13 cases) and 15.1% (14 cases), respectively. Median overall survival was not reach in HER-2 positive group compared with 30.9 months in negative group. (hazard ratio 0.39; 95% CI 0.12 to 1.21; p 0.089). This study could not demonstrate association between HER-2 positive and any clinicopathological features.
Conclusions
Among patients with cholangiocarcinoma, 1 of 10 cases had HER-2 overexpression.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
This study was granted by Faculty of Medicine, Khon Kaen University, Thailand (Grant Number IN64140).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
48P - Long-term clinical outcomes after the second metastasectomy in patients (pts) with resected metastatic colorectal cancer (mCRC)
Presenter: Songji Choi
Session: Poster viewing 02
49P - Ramucirumab beyond progression plus TAS 102 in patients with advanced or metastatic adenocarcinoma of the stomach or the gastroesophageal junction, after treatment failure on a ramucirumab based therapy: Final results of the phase II RE-ExPEL study
Presenter: Thorsten Goetze
Session: Poster viewing 02
50P - Linear tumor regression of rectal cancer in daily MRI during preoperative chemoradiotherapy: An insight of tumor regression velocity for personalized cancer therapy
Presenter: Sea-Won Lee
Session: Poster viewing 02
51P - Efficacy and safety of sintilimab as first-line therapy in patients with microsatellite instability-high metastatic colorectal cancer: A real-world study
Presenter: Caiyun Nie
Session: Poster viewing 02
53P - Baseline PET/CT deep radiomics signature apply for identifying bevacizumab sensitivity of RAS-mutant colorectal cancer liver metastases patients
Presenter: Wenju Chang
Session: Poster viewing 02
54P - Efficacy of total neoadjuvant therapy (TNT) in rectal cancer: A meta-analysis of randomized controlled trials
Presenter: Yakup Ergün
Session: Poster viewing 02
55P - Biodegradable and biocompatible 3D-printed scaffolds loaded with chemotherapy drugs: A new horizon for treatment of colon cancer with diffuse intraperitoneal metastasis
Presenter: Amirhosein Kefayat
Session: Poster viewing 02
56P - Clinico-pathological profile of adolescent and young adult colorectal cancer patients: Multicentre collaborative registry data from India
Presenter: Soumya Surath Panda
Session: Poster viewing 02